Optimal Meropenem Administration for Critically Ill Sepsis Patients.

Continuous administration of meropenem did not significantly decrease the composite of all-cause mortality and emergence of pandrug-resistant or extensively drug-resistant bacteria at day 28 compared to intermittent administration in critically ill patients with sepsis. The multicenter, double-blind, randomized clinical trial enrolled 607 patients and was conducted in 4 countries. The trial aimed to test the hypothesis that continuous administration of meropenem would decrease the composite outcome of new antimicrobial resistance and mortality.